NO20061489A - Formulations and method feeder to treat inflammatory bowel disease - Google Patents

Formulations and method feeder to treat inflammatory bowel disease

Info

Publication number
NO20061489A
NO20061489A NO20061489A NO20061489A NO20061489A NO 20061489 A NO20061489 A NO 20061489A NO 20061489 A NO20061489 A NO 20061489A NO 20061489 A NO20061489 A NO 20061489A NO 20061489 A NO20061489 A NO 20061489A
Authority
NO
Norway
Prior art keywords
formulations
methods
inflammatory bowel
bowel disease
treat inflammatory
Prior art date
Application number
NO20061489A
Other languages
Norwegian (no)
Inventor
John G Devane
Jackie Butler
Original Assignee
Agi Therapeutics Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US49936503P priority Critical
Priority to PCT/IB2004/003059 priority patent/WO2005021009A2/en
Application filed by Agi Therapeutics Res Ltd filed Critical Agi Therapeutics Res Ltd
Publication of NO20061489A publication Critical patent/NO20061489A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene

Abstract

Fremgangsmåter og utforminger for behandling av inflammatorisk tarmsykdom beskrives. Methods and formulations for treating inflammatory bowel disease are described. Fremgangsmåtene og utformingene omfatter, men er ikke begrenset til, fremgangsmåter og utforminger for tilførsel av effektive konsentrasjoner av 4-aminosalisylsyre og/eller 5-aminosalisylsyre til rammede områder i tarmen. The methods and embodiments include but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and / or 5-aminosalicylic acid, to affected areas of the intestine. Fremgangsmåtene og utformingene omfatter elementer for modifisert frigjøring som gjør at medikamentet tilføres til det rammede eller ønskede området. The methods and embodiments comprise modified release that allow the drug administered to the affected or desired area. Sykdommer og tilstander som kan behandles med den foreliggende oppfinnelsen omfatter Crohns sykdom og ulcerøs kolitt. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.
NO20061489A 2003-09-03 2006-04-03 Formulations and method feeder to treat inflammatory bowel disease NO20061489A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US49936503P true 2003-09-03 2003-09-03
PCT/IB2004/003059 WO2005021009A2 (en) 2003-09-03 2004-09-02 Formulations and methods of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
NO20061489A true NO20061489A (en) 2006-05-30

Family

ID=34272809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061489A NO20061489A (en) 2003-09-03 2006-04-03 Formulations and method feeder to treat inflammatory bowel disease

Country Status (13)

Country Link
US (2) US7737133B2 (en)
EP (1) EP1663253B1 (en)
JP (1) JP5108304B2 (en)
AT (1) AT489956T (en)
AU (1) AU2004267953A1 (en)
CA (1) CA2535923A1 (en)
DE (1) DE602004030353D1 (en)
ES (1) ES2353761T3 (en)
IL (1) IL173684D0 (en)
MX (1) MXPA06002048A (en)
NO (1) NO20061489A (en)
WO (1) WO2005021009A2 (en)
ZA (1) ZA200601356B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
NZ549661A (en) 2004-02-06 2010-07-30 Pharmatel R & D Pty Ltd As Tru Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
DE602005022175D1 (en) * 2004-05-28 2010-08-19 Salix Pharmaceuticals Inc Prevention, treatment and alleviation of radiation-induced enteritis
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
MX2008002283A (en) * 2005-08-24 2008-09-08 Salix Pharmaceuticals Inc Balsalazide formulations and manufacture and use thereof.
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8679545B2 (en) * 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20140010860A1 (en) 2006-05-12 2014-01-09 Isa Odidi Abuse and alcohol resistant drug composition
EP2050439B1 (en) * 2006-08-11 2016-11-23 Asahi Kasei Kabushiki Kaisha Process for production of spherical granule containing slightly water-soluble substance
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20090069247A1 (en) * 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN101553204B (en) * 2006-12-04 2013-10-30 苏佩努斯制药公司 Enhanced immediate release formulations of topiramate
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US20100104656A1 (en) * 2007-03-20 2010-04-29 Paul Wan Sia Heng Meltable Binder for Melt Granulation and/or Pelletization
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009047802A2 (en) * 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
CA2746767A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Oral formulations
JP6063377B2 (en) 2010-03-31 2017-01-18 スパーナス ファーマシューティカルズ インコーポレイテッド Stabilizing formulation of Cns compound
US8597683B2 (en) * 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
WO2013134348A1 (en) * 2012-03-07 2013-09-12 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US20170119680A1 (en) 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (en) 1980-03-20 1982-03-11
SE8002322L (en) 1980-03-26 1981-09-27 Pharmacia Ab Agents for the treatment of inflammatory bowel diseases
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
ZA8205384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8303400D0 (en) 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicylic acid and salt derav and their pharmaceutical formulation and priority over
SE8303399D0 (en) 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicylic acid and salt derav, their preparation and pharmaceutical front tell accession of the acid
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4705515A (en) 1984-10-26 1987-11-10 Alza Corporation Dosage form for administering drug of the colon
US4693895A (en) 1984-10-26 1987-09-15 Alza Corporation Colon delivery system
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int Method for targeted and controlled sale of drugs in the intestine and particularly the colon
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Colonic drug delivery system
SE9002339L (en) 1990-07-04 1992-01-05 Kabi Pharmacia Ab A therapeutic composition and its foerfarande foer framstaellning
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
FR2692484B1 (en) 1992-06-22 1995-06-30 Gouchet Franck New dosage form of 4-ASA release was controlled.
WO1995016451A1 (en) 1992-06-22 1995-06-22 Franck Arno Gouchet Tablets for the controlled release of 4-asa
AT195252T (en) 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Drug delivery device with controlled release
DK66493D0 (en) 1993-06-08 1993-06-08 Ferring A S Compositions, particularly for use in the treatment of inflammatory bowel diseases, or to achieve improved wound healing
JPH072650A (en) * 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd Release part control type preparation
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
ES2188657T3 (en) 1994-04-22 2003-07-01 Yamanouchi Pharma Co Ltd System for colon specific release of a drug.
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
JPH0840941A (en) * 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd Remedial preparation for inflammatory bowel disease
US5608048A (en) * 1995-06-05 1997-03-04 Bristol-Myers Squibb Company d4 T polymorphic Form 1 process
US6004581A (en) 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
DE19732903A1 (en) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
JP2000103732A (en) * 1998-07-28 2000-04-11 Tanabe Seiyaku Co Ltd Intestinal right place release preparation
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
CA2344680C (en) 1998-09-28 2008-11-25 Warner-Lambert Company Enteric and colonic delivery using hpmc capsules
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
ITMI991316A1 (en) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A oral pharmaceutical compositions in modified release mesalazine
DE10013029A1 (en) 2000-03-17 2001-09-20 Roehm Gmbh Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively
AU7906401A (en) 2000-07-27 2002-02-13 Univ Rutgers Therapeutic azo-compounds for drug delivery
AU6552500A (en) 2000-08-29 2002-03-13 Mepha Ag Medicament for treating intestinal diseases
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6897205B2 (en) * 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease

Also Published As

Publication number Publication date
WO2005021009A3 (en) 2007-12-27
DE602004030353D1 (en) 2011-01-13
MXPA06002048A (en) 2006-05-25
WO2005021009A2 (en) 2005-03-10
AT489956T (en) 2010-12-15
JP5108304B2 (en) 2012-12-26
CA2535923A1 (en) 2005-03-10
US7928092B2 (en) 2011-04-19
EP1663253A2 (en) 2006-06-07
ZA200601356B (en) 2007-07-25
JP2007504212A (en) 2007-03-01
AU2004267953A1 (en) 2005-03-10
EP1663253B1 (en) 2010-12-01
US20050090473A1 (en) 2005-04-28
US7737133B2 (en) 2010-06-15
US20100278917A1 (en) 2010-11-04
ES2353761T3 (en) 2011-03-04
IL173684D0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
Koch et al. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat
CY1118991T1 (en) Formulations Human antibodies for treatment relating to tnf-alpha DISORDERS
NO20070432A (en) Pyrimidinureaderivater as kinase inhibitors
RS20120201A2 (en) Methods and compositions for hepatitis c virus treatment
BRPI0415288A (en) compound, pharmaceutical composition, method of treating or preventing diseases, and method for preparing the compound
NO963499A (en) Hydroksaminsyre- and carboxylic acid derivatives, processes for their preparation and use thereof
BR0314236A (en) Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent for the prophylaxis or treatment of a viral infection in a patient for prophylactic treatment of cancer caused by oncoviruses for identifying a compound that alters the binding of an oligonucleotide with at least one viral component for purification of oligonucleotides binding to at least one viral component and for enrichment of oligonucleotides from an array of oligonucleotides
NO324440B1 (en) Quinazolinones, use of these compounds as medicament and pharmaceutical compositions using these compounds for preparing medicaments for treating diseases and an in vitro method of inhibiting KSP kinesin-based on such compounds
BRPI0403935A (en) azithromycin dosage forms with reduced side effects
FR2862536B1 (en) pharmaceutical formulations for the prolonged release of principle (s) active (s) and their particular therapeutic applications
NO20022014D0 (en) Controlled release of hydrocodone formulations
CR8380A (en) Methods for preparing and using novel compounds of stem cells and their joint
BR0311313A (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
NO20055976A (en) The method feeder and compositions using immunomodulatory compounds for the treatment and handling of cancers and other diseases
TW200500375A (en) Modified 2&#39; and 3&#39;-nucleoside prodrugs for treating flaviviridae
NZ709704A (en) Protein formulations and methods of making same
NO20063430A (en) Generally linear effervescent oral fentanyl dosage form, and methods of administering
NO329386B1 (en) Glucocorticoids-mimetic, pharmaceutical compositions and uses for the preparation of medikamenterfor treating disease
MX9709866A (en) Method of treatment for lung diseases using antisense oligonucleotides.
NO20061840A (en) Drug coatings which provide high drug addition and the method feeder apparatus for obtaining same
BR0211119A (en) Compound, a method of treating a patient who has, or in preventing a patient catching a disease or condition, the use of a compound and method for manufacturing a compound
IS6557A (en) Combination therapies of antihypertensive agents and agents that inhibit angiogenesis
BRPI0408784A (en) method for using a compound
MXPA05012842A (en) Foamable pharmaceutical compositions and methods for treating a disorder.

Legal Events

Date Code Title Description
FC2A Rejection of laid open patent application